Moderna posts Q1 2026 loss despite revenue surge
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Subscribe To Our Newsletter & Stay Updated